Form 4: Tandem Diabetes Care Executive Reports Stock Transactions
SEC Form 4 Filing
Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, reports acquisition and disposal of company stock and restricted stock units.
Summary
- On May 15, 2024, Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, reported several transactions involving the company's stock.
- Carpenter acquired 796 shares of common stock through the Employee Stock Purchase Plan at $15.64 per share.
- He also acquired 595 and 5,748 shares of common stock upon the vesting of restricted stock units (RSUs) at a price of $0.
- Shares were withheld to satisfy tax obligations related to the vesting of RSUs, with 213 and 2,051 shares withheld at a price of $47.37.
- Following these transactions, Carpenter directly owns 10,975 shares of common stock and holds 11,497 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.
Positives
- The reporting person acquired shares through the Employee Stock Purchase Plan, indicating confidence in the company's future.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.
Comparison to Industry Standards
- Executive stock transactions are a normal part of compensation and wealth management in publicly traded companies.
- Similar filings are routinely made by executives at companies like Insulet (PODD) and Dexcom (DXCM), which are competitors of Tandem Diabetes Care in the diabetes technology space.
- The details of the transactions, such as the use of ESPPs and RSUs, are standard compensation practices.
Key Dates
| Date | Description |
|---|---|
| 05/25/2022 | Date of RSU award pursuant to the 2013 Stock Incentive Plan. |
| 11/16/2023 | Start date of ESPP purchase period. |
| 05/25/2023 | Date of RSU award pursuant to the 2023 Long-Term Incentive Plan. |
| 05/15/2024 | Date of earliest transaction and ESPP purchase period end date. |
| 05/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.